title: CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
abstract: In a landmark article published in the May 1, 2001, issue of Clinical Cancer Research, Lee and colleagues reported the original preclinical studies demonstrating anticancer activity of BMS-247550 (ixabepilone) against taxane-sensitive and taxane-resistant cancers. Subsequent clinical trials established the clinical efficacy of ixabepilone, leading to its regulatory approval for the treatment of drug-resistant metastatic or locally advanced breast cancers.
authors.affiliation: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
authors.forename: Navjotsingh
authors.initials: N
authors.lastname: Pabla
authors.affiliation: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee. alex.sparreboom@stjude.org.
authors.forename: Alex
authors.initials: A
authors.lastname: Sparreboom
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy*; D001952:Bridged-Ring Compounds / Q000494:pharmacology; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D034261:Epothilones / Q000494:pharmacology*; D005260:Female; D045325:HCT116 Cells; D006801:Humans; D008870:Microtubules / Q000378:metabolism*; D043823:Taxoids / Q000494:pharmacology; D050257:Tubulin Modulators / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D034261:Epothilones; D043823:Taxoids; D050257:Tubulin Modulators; C080625:taxane; C430592:ixabepilone